pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›divarasib
drug · small molecule
save

divarasib

Phase 3updated 6mo ago
by Genentech Inc🔗 ChEMBL
Phase 3
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.

indications

indications
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying divarasib

  • phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)active not recruitingn=99
  • —An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Canceravailable
  • phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Studyrecruitingn=200
  • phase1A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)recruitingn=542
  • phase3A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Canceractive not recruitingn=338
  • phase3A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancerrecruitingn=600
  • phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Studyactive not recruitingn=920
  • phase2A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutationrecruitingn=320

News(10)

  • STAT+: RFK Jr. goes for broke in Iowa
    Kennedy on the campaign trail for MAHA, and new rules loom for U.S. investments in Chinese biotech.
    stat · 20d ago
  • STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
    Last year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:
    stat · 20d ago
  • A possible treatment for brain-eating amoebas, found in the sea
    Brain-eating amoebas are hard to treat and nearly always fatal. But researchers have isolated a compound that could help stop the disease.
    stat · 20d ago
  • STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own
    A small community tests if it can solve a crisis no one else could, for the simple reason that they have no other choice.
    stat · 21d ago
  • Opinion: Cancer vaccines are finally here. How do we get them to patients?
    “If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman Laraki.
    stat · 21d ago
  • From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
    Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…
    fiercebiotech · 21d ago
  • STAT+: Roche gets a lung cancer win with its KRAS drug divarasib
    One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.
    stat · 21d ago
  • ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
    At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
    biopharma_dive · 21d ago
  • STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
    Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial
    stat · 21d ago
  • ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
    Roche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.
    fiercebiotech · 24d ago
view all news mentions →
generic
divarasib
indication
Non-Small Cell Lung Cancer
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?